SG11202106765XA - Anti-pd-1 binding proteins and methods of use thereof - Google Patents
Anti-pd-1 binding proteins and methods of use thereofInfo
- Publication number
- SG11202106765XA SG11202106765XA SG11202106765XA SG11202106765XA SG11202106765XA SG 11202106765X A SG11202106765X A SG 11202106765XA SG 11202106765X A SG11202106765X A SG 11202106765XA SG 11202106765X A SG11202106765X A SG 11202106765XA SG 11202106765X A SG11202106765X A SG 11202106765XA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- binding proteins
- proteins
- binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862785660P | 2018-12-27 | 2018-12-27 | |
| PCT/US2019/068824 WO2020140088A1 (en) | 2018-12-27 | 2019-12-27 | Anti-pd-1 binding proteins and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202106765XA true SG11202106765XA (en) | 2021-07-29 |
Family
ID=71127358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202106765XA SG11202106765XA (en) | 2018-12-27 | 2019-12-27 | Anti-pd-1 binding proteins and methods of use thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220064302A1 (he) |
| EP (1) | EP3902822A4 (he) |
| JP (1) | JP2022516073A (he) |
| KR (1) | KR20210121046A (he) |
| CN (1) | CN113544146A (he) |
| AU (1) | AU2019414968A1 (he) |
| BR (1) | BR112021012667A2 (he) |
| CA (1) | CA3124971A1 (he) |
| IL (1) | IL284157A (he) |
| MX (1) | MX2021007692A (he) |
| SG (1) | SG11202106765XA (he) |
| WO (1) | WO2020140088A1 (he) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220056137A1 (en) * | 2018-12-27 | 2022-02-24 | Gigagen, Inc. | Anti-PD-L1 Binding Proteins and Methods of Use Thereof |
| US20240002534A1 (en) * | 2020-11-30 | 2024-01-04 | Merck Sharp & Dohme Llc | Arginase 1 binders for inhibiting arginase 1 activity |
| JP2024516645A (ja) * | 2021-04-26 | 2024-04-16 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | 抗ｃｌｅｃ１２ａ抗体及びその使用 |
| AU2022289491A1 (en) * | 2021-06-11 | 2023-12-14 | Memorial Hospital For Cancer And Allied Diseases | Anti-upar antibodies and uses thereof |
| CN118159558A (zh) * | 2021-09-02 | 2024-06-07 | 纪念斯隆-凯特琳癌症中心 | 抗dll3抗体和其用途 |
| WO2024044732A2 (en) * | 2022-08-25 | 2024-02-29 | Bright Biopharmaceutical | Multispecific antibodies and uses thereof |
| WO2024050371A1 (en) * | 2022-08-29 | 2024-03-07 | Fred Hutchinson Cancer Center | Antibodies with novel fc modification combinations that increase antibody function |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2439273B1 (en) * | 2005-05-09 | 2019-02-27 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI595006B (zh) * | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| WO2017024515A1 (en) * | 2015-08-11 | 2017-02-16 | Wuxi Biologics (Cayman) Inc. | Novel anti-pd-1 antibodies |
| CN106939047B (zh) * | 2016-01-04 | 2021-08-31 | 江苏怀瑜药业有限公司 | 一种pd-l1抗体及其制备方法 |
| WO2017124050A1 (en) * | 2016-01-14 | 2017-07-20 | Bps Bioscience, Inc. | Anti-pd-1 antibodies and uses thereof |
| CN105754990A (zh) * | 2016-01-29 | 2016-07-13 | 深圳精准医疗科技有限公司 | 一种pd-1/ctla-4双特异性抗体的制备方法及其应用 |
-
2019
- 2019-12-27 BR BR112021012667A patent/BR112021012667A2/pt not_active Application Discontinuation
- 2019-12-27 CA CA3124971A patent/CA3124971A1/en not_active Abandoned
- 2019-12-27 AU AU2019414968A patent/AU2019414968A1/en not_active Abandoned
- 2019-12-27 MX MX2021007692A patent/MX2021007692A/es unknown
- 2019-12-27 EP EP19906400.7A patent/EP3902822A4/en not_active Withdrawn
- 2019-12-27 US US17/418,764 patent/US20220064302A1/en active Pending
- 2019-12-27 CN CN201980092671.6A patent/CN113544146A/zh active Pending
- 2019-12-27 JP JP2021537085A patent/JP2022516073A/ja active Pending
- 2019-12-27 WO PCT/US2019/068824 patent/WO2020140088A1/en unknown
- 2019-12-27 KR KR1020217023741A patent/KR20210121046A/ko unknown
- 2019-12-27 SG SG11202106765XA patent/SG11202106765XA/en unknown
-
2021
- 2021-06-17 IL IL284157A patent/IL284157A/he unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020140088A1 (en) | 2020-07-02 |
| AU2019414968A1 (en) | 2021-08-12 |
| CN113544146A (zh) | 2021-10-22 |
| IL284157A (he) | 2021-08-31 |
| KR20210121046A (ko) | 2021-10-07 |
| EP3902822A4 (en) | 2022-12-28 |
| MX2021007692A (es) | 2021-09-30 |
| US20220064302A1 (en) | 2022-03-03 |
| CA3124971A1 (en) | 2020-07-02 |
| EP3902822A1 (en) | 2021-11-03 |
| JP2022516073A (ja) | 2022-02-24 |
| BR112021012667A2 (pt) | 2022-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281783A (he) | חלבונים קושרים מסוג SIRPa ושיטות שימוש בהם | |
| IL281683A (he) | חלבונים קושרי dll3 ושיטות לשימוש | |
| IL275782A (he) | חלבונים קושרי אנטיגן רב-ספציפיים ושיטות לשימוש בהם | |
| IL276731A (he) | נוגדנים נגד cd73 ושיטות לשימוש בהם | |
| IL288071A (he) | חלבונים קושרי epcamושיטות לשימוש | |
| IL261666A (he) | חלבונים קשורים ושיטות לשימוש בהם | |
| EP3635013A4 (en) | NECTIN-4 BINDING PROTEINS AND PROCESSES FOR USE | |
| IL261432A (he) | חלבונים קושרים מושרים ושיטות לשימוש | |
| IL278821A (he) | נוגדנים אנטי- sirpa ושיטות לשימוש בהם | |
| SG11202010909RA (en) | Anti-msr1 antibodies and methods of use thereof | |
| IL284157A (he) | חלבונים קושרים כנגד pd-1 ושיטות לשימוש בהם | |
| IL279201A (he) | חלבונים קושרים רב-ספציפיים ושיטות לשימוש בהם | |
| IL269074A (he) | חלבונים הקושרים אנטיגנים אנטי-tigit ושיטות לשימוש בהם | |
| IL284156A (he) | חלבונים קושרים כנגד ctla-4 ושיטות לשימוש בהם | |
| IL270214A (he) | נוגדנים אנטי–סורטילין ושיטות לשימוש בהם | |
| IL279648A (he) | נוגדנים אנטי-sirp-בתא 1 ושיטות לשימוש בהם | |
| IL283884A (he) | נוגדנים כנגד il-36 ושיטות לשימוש בהם | |
| IL280338A (he) | נוגדנים אנטי- siglec-5ושיטות לשימוש בהם | |
| IL283231A (he) | גורמי קישור dpep-1 ושיטות שימוש | |
| IL279227A (he) | נוגדנים אנטי- siglec-7 ושיטות לשימוש בהם | |
| IL284364A (he) | חלבונים קושרים כנגד pd-l1 ושיטות לשימוש בהם |